MarketInOut Stock Screener Log In | Sign Up
 

Replimune Group Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/16/2026
Replimune Group Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,073.16 mln
Float88.61 mln
Earnings Date10/29/2026

Piotroski F-Score

1 / 9
Very weak

1-Year Forecast

19.50
Transformational upside

Relative Strength

17 / 100
Significantly lagging

Debt / Equity

1.06
Elevated leverage

ROE

-137
Deeply negative

ROA

-83.55
Deeply negative

Business Description

Replimune Group is a biotechnology company focused on developing cancer treatments that use modified viruses to trigger the body's immune system to fight tumors. Founded in 2015 and based in Woburn, Massachusetts, the company has several therapies in development, with its most advanced candidate targeting a broad range of solid tumors. Its pipeline also includes treatments designed to further strengthen the immune response by blocking proteins that would otherwise suppress it or by directly stimulating key immune cells.

Key Fundamentals

EPS-2.96
ROE-137
ROIC-403
ROA-83.55
Interest Cover-31.46
EBITDA, mln-282
EV / EBITDA-4.63
EV / EBIT-4.52

Quote Details

Last 10.86
Change -0.89 (-7.57%)
Open 11.73
Volume 1,710,478
Turnover 18,575,790
Average Volume 2,034,572

Financial Ratios

Leverage Ratio2.39
Current Ratio5.23
Price / Book10.51
Price / Tangible Book10.51
Debt / Equity1.06

Financial Strength

Piotroski F-Score 1 / 9
1-Year Target Price19.50
Short Ratio10.98
Short % of Float34.24

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -19.08% 9 / 100   
1 Month -15.62% 21 / 100   
2 Months -1.18% 56 / 100   
6 Months 396% 100 / 100   
1 Year 150% 98 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us